Low Dose Aspirin Alerts in High-Risk Pregnancies

Geisinger Health

Status: Active, not recruiting

Conditions: Economics, Behavioral; Preeclampsia; Clinical Decision Support Systems; Aspirin

Treatments: Behavioral: Electronic health record best practice alert

Study type: Interventional

Funder types: Other

Identifiers

NCT05802940

LDA BPA

Details and patient eligibility

About

The goal of this study is to assess the effect of an electronic health record (EHR) clinical decision support tool, also known as a best practice alert (BPA), on healthcare provider recommendations for low dose aspirin use in a high-risk pregnant patient population. The investigators hypothesize that the implementation of the EHR BPA tool will increase the healthcare provider's recommendation for low dose aspirin compared to current standard care.

Full description

Low dose aspirin (LDA) has been found to reduce the incidence of preeclampsia in high-risk pregnant patients. At a health system serving central and northeastern Pennsylvania, electronic health record data reveal that clinicians recommend an LDA regimen to only 60% of eligible high-risk pregnant patients, suggesting the need and opportunity for increased LDA recommendation. This study will assess the efficacy of an electronic health record based clinician-facing interruptive clinical decision support tool/best practice alert (BPA) aimed at increasing LDA recommendation for pregnant patients who are at high risk of preeclampsia.

Up to 704 patients will be randomized to account for possible 10% miscarriage and early termination rate as we require outcome data on a total of 640 patients for adequate power. Eligible patients will be randomized to a control group, where the clinician receives no BPA, and one experimental group, where the provider receives a BPA noting the patient is at high-risk and recommend the provider order LDA. If LDA is not recommended, there will be a required acknowledgment reason from the provider noting a rationale for not initiating a LDA regimen.

Enrollment: 839 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Receiving prenatal care within Geisinger
• Initial prenatal visit prior to 28 weeks gestation
• Determined to be high risk for preeclampsia based on the modified United States Preventive Services Task Force and American College of Obstetrics and Gynecology criteria (at least 1 high risk factor)

Exclusion criteria

• Not pregnant
• No prenatal visit prior to 28 weeks gestation
• Maternal-Fetal Medicine only visits
• Not meeting the modified USPSTF high-risk criteria
• Contraindication to aspirin, including allergy

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

839 participants in 2 patient groups

Best practice alert (BPA) intervention group

Active Comparator group

Description:

An electronic health record best practice alert (BPA) will alert healthcare providers to recommend low dose aspirin for pregnant patients at high-risk for preeclampsia. This alert also allows the healthcare provider to order an over-the-counter-prescription for low dose aspirin and automatically documents LDA in the patient's medication list.

Treatment:

Behavioral: Electronic health record best practice alert

Standard care group

No Intervention group

Description:

Healthcare provider's recommendation for aspirin in patients at high-risk for preeclampsia will be based on current practice (no alerts) and the healthcare provider's knowledge.